Kymera Therapeutics, Inc. announced the presentation of preclinical data for KT-621, a potent, selective, oral degrader of STAT6, at the European Academy of Dermatology and Venereology (EADV) Congress on September 25, 2024. The data highlighted KT-621's differentiated profile as a potential once-daily oral treatment for TH2-driven allergic and atopic diseases.
Preclinical studies demonstrated that KT-621 was exquisitely selective for STAT6 and fully blocked the function of IL-4/IL-13, critical cytokines in allergic and atopic inflammation. Its picomolar potency was comparable or superior to dupilumab in key human TH2 cellular assays. In mouse models of atopic dermatitis and asthma, KT-621 showed robust in vivo STAT6 degradation and marked reduction of total serum IgE, comparable to dupilumab's activity.
New data also showed KT-621's strong degradation of STAT6 in human iPSC-derived sensory neurons, inhibiting IL-13-induced itch- and pain-related gene transcripts. This suggests the potential to alleviate these symptoms in atopic dermatitis patients. The company intends to initiate Phase 1 testing for KT-621 in the second half of 2024, with data expected in the first half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.